Par Drugs and Chemicals Limited — Important, 14-02-2025: Updates

The Board of Directors of Par Drugs and Chemicals Limited convened and approved the unaudited financial results for the quarter and nine months ended December 31, 2024. Key highlights include total revenue of ₹2,165.29 crore, a slight increase over the previous quarter’s ₹2,422.82 crore, supported by an operational revenue of ₹2,138.11 crore, reflecting steady demand. Expenditures totaled ₹2,088.06 crore, primarily driven by material costs, resulting in a profit before tax of ₹77.24 crore. The company reported a profit for the period at ₹57.80 crore, with earnings per share standing at ₹0.47. Notably, the board approved advertising the results in prominent newspapers to ensure shareholder visibility. The company also noted a clean slate regarding investor grievances, showcasing effective handling of investor relations. The outlook remains positive, with management emphasizing ongoing operational stability and a proactive stance toward market expansion. Investors should monitor the company's performance, particularly in improving revenue growth and cost management moving forward.